Latest Blogs

Aug 05, 2020
Hospitals and clinics are restricting visitors to limit the risk of exposure to COVID-19, but this precaution can be difficult for family caregivers who are struggling to get the information they need to help their loved ones.
Aug 04, 2020
Ahead of the ASCO20 Virtual Education Program, Mr. David Whitaker of Choose Chicago sends his best wishes and gratitude on behalf of the city where the ASCO Annual Meeting is traditionally held.
Jul 27, 2020
Ten years after losing my mom to breast cancer, I find myself reflecting on who I am today and what I have learned from the loss and grief that propelled me to relocate across the globe and dedicate my career to serving patients with cancer. 
Jul 23, 2020
Sometimes the best treatment isn't a medical intervention, but an emotional one, as Dr. Dawood Findakly discovered when a patient seemed to lose his will to live.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Jun 05, 2016
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
Feb 16, 2016
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.
Jan 06, 2016
One of the most frequent questions I hear in my clinic is, “Are we making any progress?” or, “Is there anything new out there?” The answer is always yes, or more properly, YES!
Nov 04, 2015
I think the facet of cancer most commonly misunderstood by non-scientists (patients/families) is heterogeneity. Several presentations at the Prostate Cancer Foundation Annual Retreat touched on this theme.
Aug 05, 2015
Looking back on the 1976 Bonadonna study using CMF chemotherapy in women with breast cancer and positive axillary nodes, I consider what went wrong in the search for similarly effective treatment of prostate cancer.
Jun 03, 2015
As someone who is interested in prostate cancer almost exclusively in my practice, listening to Dr. Nicholas James present the data from the STAMPEDE trial was of high interest.

Pages